Comstock Capital Value Fund on Nuvalent Inc.
Thesis
GSK agreed to acquire Nuvalent for $124.00 per share in cash. The transaction values the oncology company at approximately $9 billion. The event-driven return depends on shareholder and regulatory approvals and an expected third-quarter 2026 close.
“The transaction is subject to shareholder, as well as regulatory approvals and is expected to close in the third quarter of 2026.”
Key risks
- The announced acquisition may not be completed
- Regulatory approvals may delay closing